BSE filing, NSE: AARTIDRUGS. Summary written from the filing by ALFA Finder's alert engine.
Aarti Drugs Ltd: key numbers
- Share price
- ₹446.05
- Market cap
- ₹4,071 Cr
- Revenue (annual)
- ₹2,565 Cr
- Net profit (annual)
- ₹194.9 Cr
- P/E (TTM)
- 17.8×Sector 42.0×
- Promoter holding
- 54.07%-0.36% QoQ
- FII holding
- 2.26%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Drugs Ltd
All →Aarti Drugs Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue Rs 826.2 Cr (+27% YoY), EBITDA Rs 137.9 Cr (16.6% margin, +370 bps), PAT Rs 82.8 Cr (+83%). Specialty chemicals nearly doubled; formulations grew 58%.
Aarti Drugs Results Update
Aarti Drugs reports Q2 FY27 revenue of ₹828.8 Crore and PAT of ₹82.8 Crore, up 83% YoY. Results reflect record quarterly EBITDA and margin expansion.
Aarti Drugs Q2 FY27 Results: Net Profit ₹82.8 Cr, Up 83.2% YoY
Aarti Drugs Ltd reported revenue from operations of ₹826.2 Cr (+26.6% YoY) and net profit of ₹82.8 Cr (+83.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹82.8 Cr · +83.2% YoY
Aarti Drugs Board Meeting Date
Aarti Drugs Ltd intimated BSE and NSE of a board meeting on November 3, 2026, to consider audited financial results for the quarter and half year ended September 30, 2026. Trading window remains closed until 48 hours after results declaration.
Aarti Drugs Other Announcement
The company submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI Listing Regulations.
Aarti Drugs Other Announcement
Aarti Drugs has updated its list of authorized personnel for determining materiality of events and making stock exchange disclosures, effective October 1, 2026.
Other business update announcements
All →Zydus Lifesciences Business Update
Zydus Lifesciences' subsidiary presented Phase 2b trial data for investigational saroglitazar in MASH at AASLD 2026. The drug showed higher steatohepatitis resolution than placebo, but its safety and effectiveness for this use are not yet established.
Rajshree Sugars & Chemicals Business Update
Rajshree Sugars reported October 2026 operational data for its three sugar units. Sugar sales were 17,849 MT, with no cane crushed during the month.
Fino Payments Bank Business Update
Fino Payments Bank's October 2026 update showed deposits crossing Rs 3,000 Crore for the first time. Loan referral disbursals rose 316% year-on-year to Rs 301 Crore.
Ugar Sugar Works Business Update
Ugar Sugar Works has informed the exchanges that crushing for the 2026-27 season started at its Ugar Unit on 06 Nov 2026. Crushing will ramp up to full capacity over time.
GSM Foils Business Update
GSM Foils Limited reported Net Sales of Rs. 14,63,47,636 for October 2026, with April-October cumulative sales of Rs. 1,59,69,98,607. The monthly sales update is filed under Regulation 30.
- Value
- ₹14.63 Cr
Runwal Enterprises Business Update
Runwal Enterprises adopted a fair disclosure code for unpublished price sensitive information under SEBI PIT Regulation 8. The code is hosted on the company website.